Cancer and the Complement Cascade

被引:204
作者
Rutkowski, Martin J. [1 ]
Sughrue, Michael E. [1 ]
Kane, Ari J. [1 ]
Mills, Steven A. [1 ]
Parsa, Andrew T. [1 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94143 USA
关键词
ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE-CELLS; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; EXTRACELLULAR-MATRIX; REGULATORY PROTEINS; SUBLYTIC C5B-9; FACTOR-BETA; CHOROIDAL NEOVASCULARIZATION; MESENCHYMAL TRANSITION;
D O I
10.1158/1541-7786.MCR-10-0225
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite significant research on the role of inflammation and immunosurveillance in the immunologic microenvironment of tumors, little attention has been given to the oncogenic capabilities of the complement cascade. The recent finding that complement may contribute to tumor growth suggests an insidious relationship between complement and cancer, especially in light of evidence that complement facilitates cellular proliferation and regeneration. We address the hypothesis that complement proteins promote carcinogenesis and suggest mechanisms by which complement can drive the fundamental features of cancer. Evidence shows that this diverse family of innate immune proteins facilitates dysregulation of mitogenic signaling pathways, sustained cellular proliferation, angiogenesis, insensitivity to apoptosis, invasion and migration, and escape from immunosurveillance. Given that the traditionally held functions for the complement system include innate immunity and cancer defense, our review suggests a new way of thinking about the role of complement proteins in neoplasia. Mol Cancer Res; 8( 11); 1453-65. (C) 2010 AACR.
引用
收藏
页码:1453 / 1465
页数:13
相关论文
共 163 条
[1]   C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and β-Glucan [J].
Allendorf, DJ ;
Yan, J ;
Ross, GD ;
Hansen, RD ;
Baran, JT ;
Subbarao, K ;
Wang, L ;
Haribabu, B .
JOURNAL OF IMMUNOLOGY, 2005, 174 (11) :7050-7056
[2]   Molecular cloning and characterization of the human anaphylatoxin C3a receptor [J].
Ames, RS ;
Li, Y ;
Sarau, HM ;
Nuthulaganti, P ;
Foley, JJ ;
Ellis, C ;
Zeng, ZZ ;
Su, K ;
Jurewicz, AJ ;
Hertzberg, RP ;
Bergsma, DJ ;
Kumar, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (34) :20231-20234
[3]   Complement proteins are present in developing endochondral bone and may mediate cartilage cell death and vascularization [J].
Andrades, JA ;
Nimni, ME ;
Becerra, J ;
Eisenstein, R ;
Davis, M ;
Sorgente, N .
EXPERIMENTAL CELL RESEARCH, 1996, 227 (02) :208-213
[4]  
BAATRUP G, 1994, EUR J SURG, V160, P503
[5]   RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase [J].
Badea, T ;
Niculescu, F ;
Soane, L ;
Fosbrink, M ;
Sorana, H ;
Rus, V ;
Shin, ML ;
Rus, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (01) :502-508
[6]   Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes [J].
Badea, TC ;
Niculescu, FI ;
Soane, L ;
Shin, ML ;
Rus, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (41) :26977-26981
[7]   Sublytic terminal complement attack induces c-fos transcriptional activation in myotubes [J].
Badea, TD ;
Park, JH ;
Soane, L ;
Niculescu, T ;
Niculescu, F ;
Rus, H ;
Shin, ML .
JOURNAL OF NEUROIMMUNOLOGY, 2003, 142 (1-2) :58-66
[8]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[9]  
BAMBERG CE, J BIOL CHEM, V285, P7633
[10]   TERMINAL COMPLEMENT PROTEINS C5B-9 RELEASE BASIC FIBROBLAST GROWTH-FACTOR AND PLATELET-DERIVED GROWTH-FACTOR FROM ENDOTHELIAL-CELLS [J].
BENZAQUEN, LR ;
NICHOLSONWELLER, A ;
HALPERIN, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :985-992